"T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body\u2019s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia"@en . "In preclinical studies comparing T131 to Avandia, T131 demonstrated superior potency and an improved side effect profile. In these studies, T131 treatment did not result in fluid retention or cardiac hypertrophy. In Phase 1 studies with T131, all doses were well tolerated and no serious adverse events were observed. "@en . . . . . "T131, an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body\u2019s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body\u2019s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia."@en . "Investigated for use/treatment in diabetes mellitus type 2."@en . . . "T131"@en . . . . . . . . . "investigational"@en . . "INT-131"@en . . . . . . . . . . . . . . . . .